Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Nicola Normanno, Antonio Avallone, Tiziana Latiano, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Giuseppe Santabarbara, Carmine Pinto, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
rechallenge anti-EGFR
immunotherapy
skin toxicity
mCRC
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/644e2914914c48e9b39e0f6cb9eac8c7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/644e2914914c48e9b39e0f6cb9eac8c7

Ejemplares similares